JP2019099571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019099571A5 JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024045935A JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017228661 | 2017-11-29 | ||
| JP2017228661 | 2017-11-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Division JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019099571A JP2019099571A (ja) | 2019-06-24 |
| JP2019099571A5 true JP2019099571A5 (enExample) | 2022-01-06 |
| JP7461104B2 JP7461104B2 (ja) | 2024-04-03 |
Family
ID=66975925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018223465A Active JP7461104B2 (ja) | 2017-11-29 | 2018-11-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2024045935A Active JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Active JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7461104B2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110618208A (zh) * | 2019-09-10 | 2019-12-27 | 威海迪素制药有限公司 | 一种（s）-（+）-3-羟基四氢呋喃对映异构体含量检测方法 |
| JP7711074B2 (ja) * | 2020-02-07 | 2025-07-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7569443B2 (ja) * | 2020-07-20 | 2024-10-17 | エコジーン インコーポレイテッド | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
| EP4211133A4 (en) * | 2020-09-07 | 2024-11-27 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| US20230331732A1 (en) * | 2020-09-10 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| HRP20251161T1 (hr) | 2021-09-27 | 2025-11-21 | Terns Pharmaceuticals, Inc. | Benzimidazol karboksilne kisele kao agonisti glp-1r |
| CA3236708A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CA3252943A1 (en) | 2022-02-23 | 2023-08-31 | Terns Pharmaceuticals, Inc. | COMPOUNDS AS GLP-1R AGONISTS |
| CN119497611A (zh) * | 2022-05-11 | 2025-02-21 | 伊莱利利公司 | Glp1片剂组合物 |
| US20250302809A1 (en) * | 2022-05-11 | 2025-10-02 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
| KR20250111397A (ko) * | 2022-12-13 | 2025-07-22 | 일라이 릴리 앤드 캄파니 | 제2형 당뇨병 (t2d), 비만, 또는 적어도 하나의 체중 관련된 동반질환이 있는 과체중을 갖는 대상체를 치료하기 위한 오르포르글리프론의 투약 요법 |
| WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| KR20250121439A (ko) * | 2022-12-19 | 2025-08-12 | 일라이 릴리 앤드 캄파니 | Glp1 ra 및 그의 중간체의 제조 방법 |
| CN121002015A (zh) * | 2023-01-17 | 2025-11-21 | 重庆复尚源创医药技术有限公司 | Glp-1r激动剂及其用途 |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| AU2024251995A1 (en) | 2023-04-07 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| JP2025538520A (ja) * | 2023-06-29 | 2025-11-28 | ウェイン バイオテクノロジー カンパニー，リミテッド | Ｇｌｐ－１受容体アゴニスト並びにその調製方法及び使用 |
| CN120077044A (zh) * | 2023-06-30 | 2025-05-30 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| TW202508571A (zh) * | 2023-07-28 | 2025-03-01 | 大陸商上海翰森生物醫藥科技有限公司 | 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025097835A1 (zh) | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265585B2 (en) * | 2002-08-26 | 2008-07-03 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| EP2591675A1 (en) * | 2006-11-27 | 2013-05-15 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| BRPI1013579A2 (pt) * | 2009-03-30 | 2020-11-03 | Transtech Pharma, Inc. | derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos |
| WO2014122067A1 (en) * | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
-
2018
- 2018-11-29 JP JP2018223465A patent/JP7461104B2/ja active Active
-
2024
- 2024-03-22 JP JP2024045935A patent/JP7767492B2/ja active Active